Tag: supplemental Biologics License Application (sBLA)

Dupixent (dupilumab)

FDA Accepts Dupixent® (dupilumab) for Priority Review in Patients Aged 12...

If approved, Dupixent would be the first medicine available in the U.S. indicated to treat eosinophilic esophagitis.